Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Herceptin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.

Roche cites COVID-19 and biosimilars in Q2 decline

Roche cites COVID-19 and biosimilars in Q2 decline

Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug The drug presents a new challenge to Roche’s dominant position in the HER2-positive breast cancer market, which includes a trio of targeted treatments – Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla ... The FDA approval and EMA

Cortellis Drugs to Watch in 2020 report

Cortellis Drugs to Watch in 2020 report It has entered into a market dominated by Herceptin and other HER2-targeted therapies such as Perjeta and Tykerb.

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA Last year, sales of Herceptin were flat overall at around $7bn, but fell 16% in Europe and Japan as biosimilars started to gather momentum. ... Perjeta has been growing strongly – rising a third to $2.8bn last year – thanks to data showing it

Seattle Genetics wins FDA priority review for oral HER2 drug

Seattle Genetics wins FDA priority review for oral HER2 drug Roche dominates the HER2 market, with a portfolio of products that includes Herceptin, Kadcyla and Xeloda. ... breast cancer patients who have received prior treatment with a taxane and Herceptin.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics